Experts applaud Amylyx for keeping its promise to withdraw ALS drug Relyvrio after trial failure
04 Apr 2024
Phase 3Clinical Trial Failure
When Amylyx brought its ALS drug before the FDA in 2022, the biotech faced questions about what it would do if a crucial Phase 3 trial failed.
On Thursday, the
company announced
that it would pull the drug from the market less than a month after it
failed to show
that it slowed the disease better than a placebo. It’s a blow to Amylyx, which will let go about 70% of its workforce, but the move is earning praise for following through on its promise from 2022 that it would do “what’s right for patients,” as co-CEO Justin Klee pledged at the time.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.